PMC9837085_01
Preoperative and postoperative pituitary magnetic resonance imaging (MRI). Preoperative postcontrast T1 sagittal (A) and T2 coronal (B) pituitary MRI demonstrating a 2.1 x 2.0 x 2.2-cm sellar mass with suprasellar extension compressing the optic chiasm without evidence of cavernous sinus invasion. Postoperative T1 coronal (C) and T1 sagittal (D) MRI showing no definitive mass residual or recurrence.
gr1.jpg
PMC9837085_01_gr1.jpg
fig1
Pituitary MRI demonstrated a 2.1 x 2.0 x 2.2-cm sellar mass with suprasellar extension (Fig. 1). Pituitary MRI 32.5 months postoperatively (Fig. 1) showed no definitive tumor residual.
Histopathology of the pituitary adenomas. Two separate adenomas were present on the surgical specimen that were separated by tongues of compressed pituitary gland (A, hematoxylin and eosin; B, Wilder reticulin). The larger tumor was composed of medium-sized cells with eosinophilic to clear cytoplasm and central nuclei with homogeneous chromatin pattern (C). The tumor cells expressed SF1 (E) and beta-follicle-stimulating hormone (G). The tumor was also immunoreactive for beta-luteinizing hormone and alpha-subunit of glycoproteins (not shown). The second adenoma was composed of smaller eosinophilic cells with central hyperchromatic nuclei (D). The tumor cells expressed PIT1 (F) and prolactin (H). (A, C, D) Hematoxylin and eosin. (B) Wilder reticulin (B). (C-F) Immunohistochemistry for SF1 (E), PTI1 (F), beta-follicle-stimulating hormone (G), and prolactin (H). Original magnifications: x10 (A, B, E, F) and x40 (C, D, G, H).
gr2.jpg
PMC9837085_01_gr2.jpg
fig2
The larger adenoma was immunopositive for beta-FSH, beta-LH, ASU, and SF1 in a widespread manner (Fig. 2).